Summary
A single oral solution dose (40 mg/m2) of 14C-prednimustine was administered to each of four cancer patients. Plasma, urine, and feces were collected at appropriate times and analyzed for total radioactivity. Plasma samples were analyzed for prednimustine. Peak plasma levels of radioactivity (1–3 μg 14C-prednimustine equivalents) occurred at 1.5–3 h in three patients and at 5–6 h in one patient. No intact prednimustine was detected in the plasma; this means that if present, it would be at a concentration of 0.02 μg/ml or less and would account for less than 1% of the total drug-related material at the time of peak plasma levels. Solvent-extractable metabolites had a plasma half-life of about 8 h or less. By 24 h essentially all the plasma radioactivity appeared to be covalently bound, and it was eliminated slowly with an estimated terminal elimination half-life of about 10 days. Rapid urinary excretion occurred in the first 24 h, and 40%–60% of the dose was recovered in the urine in 72 h. Although prednimustine was well absorbed, the ester was subject to extensive presystemic metabolism and was not present in the systemic circulation after oral administration.
Similar content being viewed by others
Abbreviations
- HPLC:
-
high-performance liquid chromatography
- PEG:
-
polyethylene glycol
References
Beckman Instruments Inc (1977) Applications of Quench Monitoring by Compton Edge: The H#. Technical Report 1096-NUC-77-2T
Brandt L, Könyves I (1977) Therapeutic effect of prednimustine (Leo 1031) in various types of leukaemia. Eur J Cancer 13:393
Brandt L, Könyves I (1978) Use of Prednimustine for remission inducation without drug-induced bone marrow applasia in adult acute non-lymphocytic leukaemia (ANLL). Med Oncology 3:521
Brandt L, Könyves I, Moller TR (1975) Therapeutic effect of Leo 1031, an alkylating corticosteroid ester in lymphoproliferative disorders. I. Chronic lymphocytic leukaemia. Acta Med Scand 197:317
Catanc R, Kaufman JH, Madajewicz S, Mittelman A, Murphy GP (1978) Prednimustine therapy of advanced prostatic cancer. Br J Urol 50:29
Clinical Screening Cooperative Group of E.O.R.T.C. (1977) A phase II clinical trial of Prednimustine. Biomedicine 27:158
Evenaar AH, Wins EHR, Putten LMV (1973) Cell killing effectiveness of an alkylating steroid (Leo-1031). Br J Cancer 9:773
Häkansson L, Könyves I, Lindberg LG, Moller T (1978) Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031). Oncology 35:103
Johnson JE, Trope C, Mattsson W, Grundsell H, Aspegren K, Könyves I (1979) Phase II study of Leo 1031 (Prednimustine) in advanced ovarian carcinoma. Cancer Treat Reports 63:421
Kaufman JH, Hanjura GL, Mittelman A, Aungst CW, Murphy GP (1976) Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat Rep 60:277
Kirdani RY, Murphy GP, Sandberg AA (1978) Some metabolic aspects of nitrogen mustard of prednisolone. Oncology 35:47
Könyves I, Liljekvist J (1976) The steroid molecule as a carrier of cytotoxic groups. Biological characterisation of human tumours. Excerpta Medica, Amsterdam, p 98 (International congress series no 375)
Könyves I, Fex H, Högberg B (1974) Novel corticosteroid esters with alkylating properties. In: Proceedings of the Eight International Congress Chemotherapy Athens. Antineoplastic Chemotherapy 3: 791
Könyves I, Nordenskjold B, Forshell GP, Deschryver A, Westerberglarsson H (1975) Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer 11:841
Lele SB, Piver MS, Barlow J, Murphy GP (1978) Leo 1031 (NSC-134087) in gynecological malignancies. Oncology 35:101
Mattsson, W, von Eyben F, Turesson I, Wahlby S (1978) Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas. Cancer 41:112
Moller TR, Brandt L, Könyves I, Lindberg LG (1975) Therapeutic effect of Leo 1031, and alkylating corticosteroid ester in lymphoproliferative disorders II. Lymphocytic lymphoma. Acta Med Scand 197:323
Mouridsen HT, Kristensen D, Nielsen JH, Dombernowsky P (1980) Phase II trial of prednimustine L-1031 (NSC-134087) in adavanced breast cancer. Cancer 46:253
Newell DR, Hart LI, Harrap KR (1979) Estimation of chlorambucil, phenylacetic mustard, and prednimustine in human plasma by high-performance liquid chromatography. J Chromatogr 164:114
Pederson-Bjergaard, Hansen MM, Geisler CH, Nissen NI (1980) Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. Acta Med Scand 207:215
Wilkinson R, Gilby ED, Könyves I, Harrap KR (1976) Possible mechanism underlying selective antitumour effect of Leo-103. Br J Cancer 34:321
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gaver, R.C., Deeb, G., Pittman, K.A. et al. Disposition of orally administered 14C-prednimustine in cancer patients. Cancer Chemother. Pharmacol. 11, 139–143 (1983). https://doi.org/10.1007/BF00254192
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254192